Kihi-to, a herbal traditional medicine, improves Abeta(25–35)-induced memory impairment and losses of neurites and synapses by Tohda, Chihiro et al.
BioMed  Central
Page 1 of 21
(page number not for citation purposes)
BMC Complementary and 
Alternative Medicine
Open Access Research article
Kihi-to, a herbal traditional medicine, improves 
Abeta(25–35)-induced memory impairment and losses of neurites 
and synapses
Chihiro Tohda*†, Rie Naito† and Eri Joyashiki
Address: Division of Biofunctional Evaluation, Research Center for Ethnomedicine, Institute of Natural Medicine, University of Toyama, Toyama 
930-0194, Japan
Email: Chihiro Tohda* - chihiro@inm.u-toyama.ac.jp; Rie Naito - xprhh741@ybb.ne.jp; Eri Joyashiki - m0861222@ems.u-toyama.ac.jp
* Corresponding author    †Equal contributors
Abstract
Background: We previously hypothesized that achievement of recovery of brain function after
the injury requires the reconstruction of neuronal networks, including neurite regeneration and
synapse reformation. Kihi-to is composed of twelve crude drugs, some of which have already been
shown to possess neurite extension properties in our previous studies. The effect of Kihi-to on
memory deficit has not been examined. Thus, the goal of the present study is to determine the in
vivo and in vitro effects of Kihi-to on memory, neurite growth and synapse reconstruction.
Methods:  Effects of Kihi-to, a traditional Japanese-Chinese traditional medicine, on memory
deficits and losses of neurites and synapses were examined using Alzheimer's disease model mice.
Improvements of Aβ(25–35)-induced neuritic atrophy by Kihi-to and the mechanism were
investigated in cultured cortical neurons.
Results: Administration of Kihi-to for consecutive 3 days resulted in marked improvements of
Aβ(25–35)-induced impairments in memory acquisition, memory retention, and object recognition
memory in mice. Immunohistochemical comparisons suggested that Kihi-to attenuated neuritic,
synaptic and myelin losses in the cerebral cortex, hippocampus and striatum. Kihi-to also
attenuated the calpain increase in the cerebral cortex and hippocampus. When Kihi-to was added
to cells 4 days after Aβ(25–35) treatment, axonal and dendritic outgrowths in cultured cortical
neurons were restored as demonstrated by extended lengths of phosphorylated neurofilament-H
(P-NF-H) and microtubule-associated protein (MAP)2-positive neurites. Aβ(25–35)-induced cell
death in cortical culture was also markedly inhibited by Kihi-to. Since NF-H, MAP2 and myelin basic
protein (MBP) are substrates of calpain, and calpain is known to be involved in Aβ-induced axonal
atrophy, expression levels of calpain and calpastatin were measured. Treatment with Kihi-to
inhibited the Aβ(25–35)-evoked increase in the calpain level and decrease in the calpastatin level.
In addition, Kihi-to inhibited Aβ(25–35)-induced calcium entry.
Conclusion: In conclusion Kihi-to clearly improved the memory impairment and losses of neurites
and synapses.
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Background
Neuronal death, neuritic atrophy, and loss of synapses
underlie the pathogenesis of Alzheimer's [1-3]. However,
neurons with atrophic neurites may remain viable and
have the potential to remodel, even when neuronal death
has occurred in other parts of the brain. We previously
hypothesized that achievement of recovery of brain func-
tion after the injury requires the reconstruction of neuro-
nal networks, including neurite regeneration and synapse
reformation [4]. Among several traditional Chinese med-
icines, Ginseng Radix [5,6], Astragali Radix [7], and Polyg-
alae Radix [8] showed axonal extension activity after
amyloid β (Aβ) (25–35)-induced axonal atrophy. Further,
ginsenoside Rb1, a constituent of Ginseng Radix, and the
aqueous extract of Astragali Radix attenuated spatial
memory deficits and the loss of axons and synapses in the
brain of Aβ(25–35)-injected mice. Although cholineste-
rase inhibitors, such as donepezil hydrochloride, are clin-
ically used for Alzheimer's disease, they do not prevent or
reverse the underlying neurodegeneration [9] or attenuate
impairments in memory and neuronal damage in Aβ(25–
35)-injected mice [6,10].
Aβ(25–35) can be produced in Alzheimer's disease
patients by enzymatic cleavage of the naturally occurring
Aβ(1–40) [11]. Abundant reports support that Aβ(25–35)
is an active partial fragment of amyloid β. This fragment
also forms a β-sheet structure [12] and induces neuronal
cell death [12,13], neuritic atrophy [9], synaptic loss
[6,10,14]. Moreover, our previous work also demon-
strated that Aβ(25–35) and Aβ(1–42) resulted in similar
effects on neuritic atrophy and cell death at 10 μM [15].
Furthermore, a recent report showed that a single intracer-
ebroventricular (i.c.v., 15 μg) injection of Aβ(25–35)
could induce major neuropathological signs related to
early stages of Alzheimer's disease in rats [16].
Kihi-to is a herbal drug used in the Japanese-Chinese tra-
ditional medicine. Kihi-to was described to be effective for
insomnia, anemia, amnesia, depression, and neurosis in
classical literatures. However, basic researches of Kihi-to
against dementia have been very few yet. Only one meet-
ing report described that 25 patients with senile dementia
improved Mini-Mental State Examination score after 3
months administration of Kihi-to [17].
Kihi-to is composed of twelve crude drugs, some of which
(e.g., Ginseng Radix [5,6], Astragali Radix [7] and Polyg-
alae Radix [8]) have already been shown to possess neur-
ite extension properties in our previous studies. Although
a previous study by another group has demonstrated that
choline acetyltransferase activity is up-regulated by Kihi-
to in rat embryo septal cultures [18], the effect of Kihi-to
on memory deficit has not been examined. Thus, the goal
of the present study is to determine the in vivo and in vitro
effects of Kihi-to on memory, neurite growth and synapse
reconstruction.
Methods
Materials
A partial fragment of Aβ, Aβ(25–35) (Sigma-Aldrich,
Saint Louis, MO, USA), was dissolved in sterile distilled
water (in vitro experiments) or physiological saline (in
vivo experiments) at a concentration of 5 mM and was
incubated at 37°C for 4 days to allow fibril formation. A
reverse fragment, Aβ(35–35) (Sigma-Aldrich) was also
dissolved in physiological saline (in vivo experiments) at
a concentration of 5 mM and was incubated at 37°C for 4
days to allow fibril formation. Neurobasal media and B-
27 supplement were purchased from Gibco BRL (Rock-
ville, MD, USA). Mouse β-NGF was purchased from Astral
Biologicals (San Ramon, CA, USA). A monoclonal anti-
body against phosphorylated neurofilament-H (NF-H)
was purchased from Sternberger Monoclonals Incorpo-
rated (Lutherville, MD, USA). Monoclonal and polyclonal
antibodies against microtubule-associated protein 2a and
2b (MAP2), a monoclonal antibody against synapto-
physin, a polyclonal antibody against myelin basic pro-
tein (MBP) were purchased from Chemicon (Temecula,
CA, USA). A monoclonal antibody against μ-calpain and
a polyclonal antibody against calpastatin were purchased
from Biosource (Camarillo, CA, USA) and Santa Cruz Bio-
technology (Santa Cruz CA. USA), respectively.
MDL28170 was purchased from Biomol (Plymouth Meet-
ing, PA, USA). Alexa Fluor 488-conjugated goat anti-
mouse IgG and Alexa Fluor 568-conjugated goat anti-rab-
bit IgG were purchased from Molecular Probes (Eugene,
OR, USA).
Preparation of Kihi-to extract
Kihi-to is composed of twelve types of crude drugs: Gin-
seng Radix (P. ginseng C.A. Meyer), 3 g; Polygalae Radix
(P. tenuifolia Willd.), 2 g; Astragali Radix (A. membranaceus
Bunge), 3 g; Zizyphi Fructus (Zizyphus jujube Mill. var. iner-
mis Rehd.) 2 g; Zizyphi Spinosi Semen (Z. jujube Mill. var.
spinosa (Bunge) Hu ex H.F. Chou) 3 g; Angelicae Radix
(Angelica acutiloba Kitagawa) 2 g; Glycyrrhizae Radix (Gly-
cyrrhiza uralensis Fisch. ex DC.) 1 g; Atractylodis Rhizoma
(Atractylodes ovata DC.) 3 g; Zingiberis Rhizoma (Zingiber
officinale Roscoe) 1.5 g; Poria (Poria cocos Wolf) 3 g; Saus-
sureae Radix (Saussurea lappa Clarke) 1 g; and Longanae
Arillus (Euphoria longana Lam.) 3 g. All crude drugs used
were purchased from Tochimoto Tenkaido (Osaka,
Japan). The mixture of crude drugs for Kihi-to that repre-
sents one human daily dose was extracted with 600 ml of
water at 100°C for 40 min and subsequently evaporated
under reduced pressure and freeze-dried to 8.3 g of extract
powder. This Kihi-to powder was then dissolved in water.
Voucher specimen (Lot No.20060921) has been depos-
ited at our laboratory.BMC Complementary and Alternative Medicine 2008, 8:49 http://www.biomedcentral.com/1472-6882/8/49
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The three-dimensional HPLC pattern of the constituents
of Kihi-to is shown [see Additional file 1]. Kihi-to extract
(1.0 g) was dissolved with methanol (20 mL) under ultra-
sonication for 30 min followed by centrifugation at 3,000
rpm for 5 min. The supernatant was filtrated with a mem-
brane filter (0.45 μm) and then submitted for HPLC anal-
ysis (30 μL). The HPLC apparatus consisted of a Shimadzu
LC 10A (analysis system software: CLASS-M10A ver. 1.64,
Tokyo, Japan) equipped with a multiple wavelength
detector (UV 200–400 nm) (Shimadzu SPD-M10AVP,
diode array detector) and an auto injector (Shimadzu
CTO-10AC). HPLC conditions were as follows: column,
ODS (TSK-GEL 80TS, 250 × 4.6 mm i.d., TOSOH, Tokyo,
Japan); eluant, (A) 0.05 M AcONH4 (pH 3.6) (B) 100%
CH3CN (a linear gradient of 90% A and 10% B, which
changed over 60 min to 0% A and 100%, B was used, fol-
lowed by 100% B for a further 20 min); temperature,
40°C; flow rate, 1.0 mL/min.
Water maze test
Male ddY mice (7 weeks old, Japan SLC) were housed
with free access to food and water, and were kept in a con-
trolled environment (22 ± 2°C, 50 ± 5% humidity, 12-h
light cycle starting at 7:00 am). Animals were handled in
accordance with the Guidelines for the Care and Use of
Laboratory Animals of the University of Toyama, and all
protocols were approved by the Animal Care Committee
of the University of Toyama. Aβ(25–35) was dissolved in
saline at a concentration of 5 mM and incubated at 37°C
for 4 days to allow for fibril formation. The mice were
anesthetized, and Aβ(25–35) (25 nmol in 5 μl) or the
reverse non-active sequence, Aβ(35–25) (25 nmol in 5
μl), was injected into the right ventricle using the follow-
ing stereotaxic coordinates from the bregma (mm): A -
0.22, L -1.0, and V 2.5. Ten days after an i.c.v. injection of
Aβ(25–35), Kihi-to (100 mg/kg/day, p.o.), or the vehicle
(tap water, p.o.) was administered once daily for 3 days.
We previously confirmed that mice injected by Aβ(35–25)
showed similar memory activities to saline-injected mice.
At present study, we used Aβ(35–25) for making a control
group to indicate that Aβ(25–35)-induced memory defi-
cits were sequence-dependent phenomena.
The Morris water maze test was performed as follows: pur-
ple-colored water was poured into a round tank (diame-
ter, 122 cm; height, 28 cm), and a purple platform
(diameter, 12 cm) was placed 1.2 cm below the water
level in the middle of a fixed quadrant. The water temper-
ature was adjusted to 21–23°C. Memory acquisition test
was performed four times daily (60 min intervals between
tests) for 5 days. The mice were allowed to swim freely
(time limit; 60 s) to seek an invisible platform and were
left for an additional 30 s on the platform. Time spent to
reach to the platform was defined as the escape latency.
The platform position was not moved during all trials. The
pattern for the rotation of the start position was changed
daily. Mice failing to find the platform after 60 s were
manually placed on the platform. Memory-retention tests
were performed 3 days after the last training session, that
is, 8 days after the discontinuation of drug administration.
The platform was removed, and each mouse was allowed
a free 60-s swim. The number of crossings over the point
where the platform had been located was counted. Swim-
ming performance was recorded by a digital camera and
analyzed by a tracking system, EthoVision 3.0 (Noldus
Information Technology, Wageningen, The Netherlands).
Novel object recognition test
Mice underwent the novel object recognition test at four
days after the water maze retention test (i.e., 12 days after
discontinuation of drug administration). Object A (a
black vase) and object B (a glass box) were placed at a
fixed distance within in a round field (diameter, 58 cm;
height, 26.5 cm). A mouse was then placed at the opposite
edge of the field, and the number of times it made contact
with the two objects was recorded during a 5-min period
(training session). Mice were then placed back into the
same field 10 min after the training session, in which one
of the familiar objects used during the training session
was replaced with a novel object C (a white ball). The
mice were then allowed to explore freely for 5 min and the
number of times they made contact with each object was
recorded (test session). A preference index, defined as the
ratio of the number of times a mouse made contact with
any of the objects (training session) or the novel object
(test session) over the total number of times the mouse
made contact with both objects, was used to measure cog-
nitive function.
Immunohistochemistry
Four days after the novel object recognition test, mice
were killed by decapitation. The brains were quickly
removed from the skull and frozen in powdered dry ice.
The brains were cut in 12-μm coronal sections using a cry-
ostat (CM3050S, Leica, Heidelberg, Germany), and the
slices were fixed with 4% paraformaldehyde and stained
with a monoclonal antibody against phosphorylated NF-
H, MAP2, synaptophysin or MBP. Alexa Fluor 488-conju-
gated goat anti-mouse IgG and Alexa Fluor 568-conju-
gated goat anti-rabbit IgG were used as secondary
antibodies. The staining and quantification were carried
out under exactly similar conditions. The fluorescent
images were captured using a fluorescent microscope (AX-
80, Olympus, Tokyo, Japan) at 661 μm × 878 μm (stria-
tum area) or 320 μm × 425 μm (other areas), and 3 – 5
sets of serial brain slices from 3 mice were used to capture
the images for each treatment. The measuring points were
selected with 10–25 squares (fixed size of a square: 10 ×
10 μm) to cover the whole area of each region or subre-
gion (e.g., the molecular layer of the dentate gyrus). TheBMC Complementary and Alternative Medicine 2008, 8:49 http://www.biomedcentral.com/1472-6882/8/49
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background intensity was determined by staining slices
without each first antibody. Fluorescent intensities of
immuno-positive areas (after subtracting the background
intensity) in those squares were quantified using ATTO
densitography (ATTO, Tokyo, Japan).
Primary culture
Embryos were removed from pregnant Sprague-Dawley
rats (Japan SLC, Shizuoka, Japan) at 17–18 days of gesta-
tion. The cortices were dissected, and the dura mater was
removed. The tissues were minced and dissociated and
then grown in cultures with Neurobasal medium includ-
ing 12% horse serum, 0.6% D-glucose and 2 mM L-
glutamine on 8-well chamber slides (Falcon, Franklin
Lakes, NJ, USA) coated with 5 μg/ml poly-D-lysine at
37°C in a humidified incubator with 10% CO2. When
Aβ(25–35) or other compounds were added, half of the
medium in each well was replaced with fresh medium
containing 2% B-27 supplement without serum. The time
schedules of the experiments are illustrated at the bottom
of each respective figure.
Immunocytochemistry for measures of neurite length and 
expressions of calpain and calpastatin
Rat cortical neurons were cultured in 8-well chamber
slides at a density of 1.45 – 2.2 × 105 cells/cm2. For meas-
uring lengths of axons and dendrites, the cells were treated
with 10 μM Aβ(25–35) for 4 days, followed by the addi-
tion of the extract, mouse β-NGF, or vehicle (0.1%
DMSO). Five days later, the cells were fixed with 4% para-
formaldehyde and then immunostained with a mono-
clonal antibody against phosphorylated NF-H (1:1000) as
an axonal marker or a monoclonal antibody against
MAP2 (1:1000) as a dendritic marker. Alexa Fluor 488-
conjugated goat anti-mouse IgG (1:200) was used as a sec-
ond antibody. For measuring levels of calpain and calp-
astatin, the cells were incubated with 10 μM Aβ(25–35)
and 0.1 μg/ml Kihi-to or 1 nM MDL28170 simultaneously
for 2, 8, 24 96 h. The cells were fixed with 4% paraformal-
dehyde and then double-immunostained with a mono-
clonal antibody against μ-calpain (1:500) and polyclonal
antibody against MAP2, or a polyclonal antibody against
calpastatin (1:500) and a monoclonal antibody against
MAP2. Alexa Fluor 488-conjugated goat anti-mouse IgG
(1:200) and Alexa Fluor 568-conjugated goat anti-rabbit
IgG (1:200) was used as second antibodies. The fluores-
cent images were captured by a fluorescent microscope
(AX-80) at 320 μm × 425 μm, and four images were cap-
tured per treatment. The lengths of neurites that were pos-
itive for phosphorylated NF-H or MAP2 were measured
using an image analyzer Neurocyte (Kurabo, Osaka,
Japan) which detects neurite lengths. The total length of
axons or dendrites was divided by cell numbers in the
identical area to show an average length per cell. Expres-
sion levels of calpain and calpastatin in MAP2-positive
neuronal cell bodies were quantified using ATTO densi-
tography as described in a Immunohistochemistry
method.
Cell viability assessment
Rat cortical neurons were cultured in 8-well chamber
slides at a density of 1.45 × 105 cells/cm2. Cell viability
was determined by calcein staining. Cells on 8-well cham-
ber slides were rinsed by phosphate-buffer saline (PBS),
and were incubated with 6 μM calcein AM (Dojindo,
Kumamoto, Japan) for 40 min at 37°C. After rinsing by
PBS, cells were fixed by 4% paraformaldehyde and
mounted. Fluorescence images and bright field images
were simultaneously captured (four images per treat-
ment) by AX-80 microscope. The percentage of dead cell
was valued as the ratio of dead cells (calcein-negative) to
total cells. The total cell number was counted in bright-
field photos.
Ca2+ imaging
After neuronal cells were incubated with fluo-4 AM (8 μM;
Dojindo) in serum-free medium for 40 min at 37°C, the
cells were washed and incubated further without fluo-4
AM in serum-free medium for 30 min at room tempera-
ture. Then, medium was replaced with HEPES buffer (of
composition, in mM, NaCl 145; MgSO4 1; KCl 2.5; D-glu-
cose 10; CaCl21; HEPES 10; pH 7.3). Cells were placed on
a heated (37°C) stage and viewed using a confocal laser
scanning microscope (TCS-SP5, Leica Microsystems,
Tokyo, Japan). Excitation and emission wavelengths ware
488 nm and 520 nm, respectively. Time-lapse images were
recorded every 5 s from 10 s before and up to 30 s after the
drug administration. Peak fluorescence change was calcu-
lated as relative change from baseline using the formula
ΔF/F% = (F - F0)/F0 * 100.
Statistical Analysis
Statistical comparisons were performed using one-way
analysis of variance (ANOVA), repeated measures two-
way ANOVA followed by Holm-Sidak post hoc test, or
paired t-test. Values of p < 0.05 were considered signifi-
cant. The means of the data are presented together with
the SE.
Results
Kihi-to ameliorates Aβ(25–35)-induced impairments in 
spatial memory and object recognition
The densities of neurites and synapses are decreased in the
hippocampus and cerebral cortex of mice 7 days after i.c.v.
administration of Aβ(25–35), and these deficits persist for
at least 30 days (unpublished data). A pretest in a water
maze was performed 9 days after i.c.v. administration of
Aβ(25–35). At that time, the escape latency in Aβ(25–35)-
injected mice was already slightly longer than that in
Aβ(35–25)-injected mice (Figure 1A, Trial day 0). MiceBMC Complementary and Alternative Medicine 2008, 8:49 http://www.biomedcentral.com/1472-6882/8/49
Page 5 of 21
(page number not for citation purposes)
Effects of Kihi-to on Aβ(25–35)-induced spatial memory deficits Figure 1
Effects of Kihi-to on Aβ(25–35)-induced spatial memory deficits. Aβ(25–35) (25 nmol) was injected into the right lat-
eral ventricle of mice. From ten days after the injection, mice were administered vehicle (Veh, water by p.o.; DMSO by i.v., n = 
10; squares) or Kihi-to (100 mg/kg B.W., p.o., n = 9; triangles) for 3 days. The control mice (Cont, n = 8; circles) were injected 
with a reverse peptide, Aβ(35–25), and then administered vehicle. After that, memory acquisition tests were continued for 5 
days in a Morris water maze (A). Escape latencies to a hidden platform were measured. Three days after the last trial of the 
memory acquisition test, the memory retention test was performed (C). The number of crossings over the position at which 
the platform had been located was measured for 60 s. Swimming velocities of mice in the memory acquisition test (B) and the 
retention test (D) are shown. *p < 0.05 vs. Veh. (a: Repeated measures two-way ANOVA followed by Holm-Sidak post hoc 
test, c: one-way ANOVA followed by Holm-Sidak post hoc test).
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were then administered Kihi-to orally (p.o.) every day for
3 days, beginning 10 days after i.c.v. administration of
Aβ(25–35), and Morris water maze testing was per-
formed. After completing the memory acquisition test
each day for 5 days, the mice rested for 3 days. Then, mice
were subjected to a memory retention test, wherein the
number of crossings over the platform position was
counted.
The time to reach the invisible platform decreased with
each trial day in all groups. Aβ(25–35)-injected mice
receiving vehicle showed a slow decrease in the escape
latency when compared with Aβ(35–25)-injected control
mice. By contrast, Kihi-to-treated mice that were injected
Aβ(25–35) showed a relatively rapid decrease in escape
latency (Figure 1A). Repeated measures two-way ANOVA
revealed significant group effects (Kihi-to vs. Aβ(25–35)-
injected and vehicle-treated, F(1, 68) = 10.89, P = 0.004).
Swimming velocities in the memory acquisition test were
not different when comparing these three groups (Figure
1B).
The number of crossings in the retention test was signifi-
cantly lower in Aβ(25–35)-injected mice receiving vehicle
than in control mice (Figure 1C). The number of crossings
was significantly higher in the Aβ(25–35)-injected mice
receiving Kihi-to than those receiving vehicle. Swimming
velocities in the memory retention test were not different
when comparing these three groups (Figure 1D).
Visual recognition memory was assessed using a novel
object recognition test. Compared with the training ses-
sion, control mice and Aβ(25–35)-injected mice receiving
Kihi-to showed significantly more frequent exploratory
behaviors to a novel object than a familiar object (Figure
2). Used dose of Kihi-to, 100 mg/kg/day is similar to
human daily dose (approximately 125 mg/kg/day), and
was shown as a maximal effective dose by our previous
experiment.
Kihi-to increases the density of neuritis, synapses and 
myelin in the brain of Aβ(25–35)-injected mice
Following the memory retention test, the levels of P-NF-
H, MAP2, synaptophysin and myelin basic protein (MBP,
a myelin marker) were measured in the brains of the mice
by immunohistochemistry. The brain regions assessed
included three cortical regions (frontal cortex, parietal
cortex and perirhinal cortex), seven subregions in three
hippocampal regions (CA1, CA3, and dentate gyrus), and
the striatum. In case of MBP, cortical regions (e.g., stria-
tum, corpus callosum) were selected for assessment, as
those regions are myelin-rich. Expression levels of P-NF-H
were decreased in all regions of Aβ(25–35)-injected mice
receiving vehicle compared to control mice, and adminis-
tration of Kihi-to resulted in significant increases in P-NF-
Effects of Kihi-to on Aβ(25–35)-induced object recognition  memory deficits Figure 2
Effects of Kihi-to on Aβ(25–35)-induced object recog-
nition memory deficits. Aβ(25–35) (25 nmol) was 
injected into the right lateral ventricle of mice. From ten days 
after the injection, mice were administered vehicle (V, water 
by p.o.; DMSO by i.v., n = 10) or Kihi-to (K, 100 mg/kg B.W., 
p.o., n = 9) for 3 days. The control mice (C, n = 8) were 
injected with a reverse peptide, Aβ(35–25) and then adminis-
tered vehicle. Twelve days after the last drug administration, 
a novel object recognition test was performed (see drug 
administration schedule in Figure 1). A mouse was placed in 
the field, and the number of times it made contact with the 
two objects was recorded for 5 min (training session). Mice 
were placed back into the same field 10 min after the training 
session, in which one of the familiar objects used during the 
training session was replaced with a novel object. The mice 
were then allowed to explore the area freely for 5 min, and 
the amount of time spent exploring each object was 
recorded (test session). The preference index was defined as 
the ratio of the number of times a mouse made contact with 
any one of the objects (training session) or the novel object 
(test session) over the total number of times the mouse 
made contact with both objects. *p < 0.05 vs. Veh. (paired t-
test).
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Effects of Kihi-to on Aβ(25–35)-induced decreases in axons Figure 3
Effects of Kihi-to on Aβ(25–35)-induced decreases in axons. Aβ(25–35) (25 nmol) was injected into the right lateral ventricle 
of mice. From ten days after the injection, mice were administered vehicle (V, water by p.o.; DMSO by i.v.) or Kihi-to (K, 100 
mg/kg B.W., p.o.) for 3 days. The control mice (C) were injected with a reverse peptide, Aβ(35–25) and then administered 
vehicle. After the novel object recognition test (Figure 2), brain slices were immunostained with phosphorylated neurofila-
ment-H (P-NF-H) antibody. P-NF-H-positive areas were quantified in the stratum oriens and stratum radiatum in CA1, the 
stratum oriens, stratum radiatum and stratum lucidum in CA3, the molecular layer and hilus in the dentate gyrus (DG), the 
parietal cortex, perirhinal cortex, frontal cortex, and the striatum. *p < 0.05 vs. Veh. n = 3. (one-way ANOVA followed by 
Holm-Sidak post hoc test).
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H expression levels in CA1 radiatum, dentate gyrus, pari-
etal cortex, perirhinal cortex and the striatum (Figures 3
and 7).
Expression levels of MAP2 were also decreased in all brain
regions of Aβ(25–35)-injected mice receiving vehicle
compared to control mice, and administration of Kihi-to
tended to increase MAP2 expression level in the dentate
gyrus and cortex (Figures 4 and 7).
Expression levels of synaptophysin were decreased in all
brain regions of Aβ(25–35)-injected mice receiving vehi-
cle, and administration of Kihi-to resulted in significant
increases in synaptophysin expression levels in CA1, the
oriens and radiatum in CA3, the molecular layer in den-
tate gyrus (Figures 5 and 7).
Expression levels of MBP were decreased in the cortex,
striatum axonal bundles and corpus callosum of Aβ(25–
35)-injected mice receiving vehicle, and administration of
Kihi-to resulted in an increase in MBP expression levels in
the perirhinal cortex (Figures 6 and 7).
Kihi-to reduces the calpain expression level in the brain of 
Aβ(25–35)-injected mice
Expression levels of calpain tended to be increased in the
cortex and CA3 of Aβ(25–35)-injected mice receiving
vehicle, and administration of Kihi-to resulted in a
decrease in calpain expression levels in those regions espe-
cially in the parietal cortex and frontal cortex (Figure 8A).
On the other hand, expression levels of calpastatin tended
to be decreased in the cortex and CA3 of Aβ(25–35)-
injected mice receiving vehicle, and administration of
Kihi-to tended to increase the calpastatin expression levels
in those regions (Figure 8B). There are not significant dif-
ferences of calpain and calpastatin expressions between
control and Aβ(25–35)-treated groups in other brain area.
Kihi-to promotes axonal and dendritic extensions in 
damaged neurons
Kihi-to was administered 4 days after treatment with
Aβ(25–35), and axon length (Figures 9A and 9B) or den-
drite length (Figures 10A and 10B) was measured after an
additional 5 days. Axon lengths and dendrite length were
shorter in the cells treated with Aβ(25–35) followed by
vehicle than in control cells. The axon and dendrite
lengths were significantly longer in the Aβ(25–35)-treated
cells when they were also treated with Kihi-to (0.1 μ g/ml)
or NGF (100 ng/ml) than when they were treated with
vehicle alone.
Kihi-to attenuates Aβ(25–35)-induced cell damage
Protective effects of Kihi-to on Aβ(25–35)-induced cell
damage were investigated. Cortical neurons were treated
by drug or vehicle (water) simultaneously with Aβ(25–
35). Four days after that, cell viability was determined by
measuring calcein uptake. [Gly14]-Humanin peptide was
used as a positive control. This mutated form peptide has
Gly14  instead of Ser14, was shown to be effective on
Aβ(25–35)-induced cell damage at lower dose (10 nM)
compared with native form of the peptide [19]. Rate of
damaged cells was increased by Aβ(25–35) treatment
compared with control (Figure 11). At a dose of 0.1 μg/
ml, Kihi-to suppressed the Aβ(25–35)-induced cell dam-
age. Treatments with [Gly14]-Humanin (10 nM) inhibited
the Aβ(25–35)-induced cell damage.
Kihi-to inhibits the calpain expression
NF-H [20] and MAP2 [21] are cleaved by the Ca2+-
dependent protease, μ-calpain. In addition, synapto-
physin colocalizes with μ-calpain [22], and dynamin, a
synaptic protein, is also a substrate of μ-calpain [23]. Fur-
ther, the expression of μ-calpain is increased in the frontal
cortex of Alzheimer's disease patients [24]. Therefore we
investigated the expression levels of calpain and calpasta-
tin in cortical neurons. We used intentionally mixed cul-
ture of neurons astrocytes oligodendrocytes and
microglias to detect changes of neurons in a circumstance
many glial cells surrounding neurons like in the brain. In
the present experimental condition, a population of neu-
rons was approximately 50%. Therefore, immunocyto-
chemistry is more suitable than Western blotting for
quantification of the neuron-specific expressions of cal-
pain and calpastatin. Calpain-positive fluorescence in the
cytosol of MAP2-positive neurons continuously increased
at 2 h to 96 h after the treatment of Aβ(25–35) (Figure
10a). A cell-permeable calpain inhibitor, MDL28170 (1
nM) and Kihi-to (0.1 μg/ml) significantly inhibited this
increase in calpain at any time points (Figure 12A). By
contrast, the expression level of calpastatin, an endog-
enous inhibitor of calpain, in the cytosol of MAP2-posi-
tive neurons continuously decreased at 2 h to 96 h after
the treatment of Aβ(25–35) (Figure 10b). MDL28170 (1
nM) and Kihi-to (0.1 μg/ml) increased the level of calp-
astatin at any time points (Figure 12B).
Kihi-to inhibits and Aβ(25–35)-induced calcium elevation
Intracellular calcium ion ([Ca2+]i) was significantly
increased in Aβ(25–35)-treated neurons (Figures 13A and
13B). In contrast, [Ca2+]i in Kihi-to (1 μg/ml) and Aβ(25–
35)-treated neurons was completely inhibited. Repeated
measures two-way ANOVA revealed a significant time and
treatment interaction (Kihi-to vs. Aβ(25–35)-injected and
vehicle-treated, F(6, 1236) = 2.657, P = 0.014).
Discussion
In the present study, behavioral memory tests clearly
showed that administration of Kihi-to for consecutive 3
days ameliorated the spatial and object recognition mem-
ories in Aβ(25–35)-injected mice (Figures 1 and 2). Kihi-BMC Complementary and Alternative Medicine 2008, 8:49 http://www.biomedcentral.com/1472-6882/8/49
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Effects of Kihi-to on Aβ(25–35)-induced decreases in dendrites Figure 4
Effects of Kihi-to on Aβ(25–35)-induced decreases in dendrites. Aβ(25–35) (25 nmol) was injected into the right lateral ventri-
cle of mice. From ten days after the injection, mice were administered vehicle (V, water by p.o.; DMSO by i.v.) or Kihi-to (K, 
100 mg/kg B.W., p.o.) for 3 days. The control mice (C) were injected with a reverse peptide, Aβ(35–25) and then administered 
vehicle. After the novel object recognition test (Figure 2), brain slices were immunostained with MAP2 antibody. MAP2-posi-
tive areas were quantified in the stratum oriens and stratum radiatum in CA1, the stratum oriens, stratum radiatum and stra-
tum lucidum in CA3, the molecular layer and hilus in the dentate gyrus (DG), and the parietal, perirhinal and frontal cortex. *p 
< 0.05 vs. Veh. n = 3. (one-way ANOVA followed by Holm-Sidak post hoc test).
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Effects of Kihi-to on Aβ(25–35)-induced decreases of synapses Figure 5
Effects of Kihi-to on Aβ(25–35)-induced decreases of synapses. Aβ(25–35) (25 nmol) was injected into the right lateral ventri-
cle of mice. From ten days after the injection, mice were administered vehicle (V, water by p.o.; DMSO by i.v.) or Kihi-to (K, 
100 mg/kg B.W., p.o.) for 3 days. The control mice (C) were injected with a reverse peptide, Aβ(35–25) and then administered 
vehicle. After the novel object recognition test (Figure 2), brain slices were immunostained with synaptophysin antibody. Syn-
aptophysin-positive areas were quantified in the stratum oriens and stratum radiatum in CA1, the stratum oriens, stratum 
radiatum and stratum lucidum in CA3, the molecular layer and hilus in the dentate gyrus (DG), the parietal cortex, perirhinal 
cortex, frontal cortex, and the striatum. *p < 0.05 vs. Veh. n = 3. (one-way ANOVA followed by Holm-Sidak post hoc test).
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Effects of Kihi-to on Aβ(25–35)-induced decreases of myelin Figure 6
Effects of Kihi-to on Aβ(25–35)-induced decreases of myelin. Aβ(25–35) (25 nmol) was injected into the right lateral ventricle 
of mice. From ten days after the injection, mice were administered vehicle (V, water by p.o.; DMSO by i.v.) or Kihi-to (K, 100 
mg/kg B.W., p.o.) for 3 days. The control mice (C) were injected with a reverse peptide, Aβ(35–25) and then administered 
vehicle. After the novel object recognition test (Figure 2), brain slices were immunostained with myelin basic protein (MBP) 
antibody. MBP-positive areas were quantified in the striatum, corpus callosum, and the parietal, perirhinal and frontal cortex. 
*p < 0.05 vs. Veh. n = 3. (one-way ANOVA followed by Holm-Sidak post hoc test).
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Effects of Kihi-to on Aβ(25–35)-induced decreases in axons, dendrites, synapses and myelins Figure 7
Effects of Kihi-to on Aβ(25–35)-induced decreases in axons, dendrites, synapses and myelins. Typical slice images of the pari-
etal and perirhinal cortex were shown for P-NF-H, MAP2, synaptophysin and MBP. Scale = 100 μm.
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Effects of Kihi-to on Aβ(25–35)-induced increases of calpain and decreases in calpastatin Figure 8
Effects of Kihi-to on Aβ(25–35)-induced increases of calpain and decreases in calpastatin. Aβ(25–35) (25 nmol) was injected 
into the right lateral ventricle of mice. From ten days after the injection, mice were administered vehicle (V, water by p.o.; 
DMSO by i.v.) or Kihi-to (K, 100 mg/kg B.W., p.o.) for 3 days. The control mice (C) were injected with a reverse peptide, 
Aβ(35–25) and then administered vehicle. After the novel object recognition test (Figure 2), brain slices were immunostained 
with μ-calpain (A) or calpastatin (B) antibody. Calpain-positive and calpastatin-positive areas were quantified in the stratum 
lucidum in CA3, and the parietal, perirhinal and frontal cortex. *p < 0.05 vs. Veh. n = 3. (one-way ANOVA followed by Holm-
Sidak post hoc test).
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Effects of Kihi-to on axonal extension following Aβ(25–35)-induced atrophy Figure 9
Effects of Kihi-to on axonal extension following Aβ(25–35)-induced atrophy. Cortical neurons were cultured for 4 
days and then treated with or without (Cont) 10 μM Aβ(25–35). Four days after the administration of Aβ(25–35), the cells 
were treated with Kihi-to (0.01 and 0.1 μg/ml), 100 ng/ml of NGF, or vehicle (Veh). Five days after treatment, the cells were 
fixed and immunostained with an antibody against phosphorylated NF-H (A). The lengths of NF-H-positive neurites (B) were 
quantified for each treatment. *p < 0.05 vs. Veh, n = 4 (one-way ANOVA followed by Holm-Sidak post hoc test). Scale bar = 
100 μm.
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Effects of Kihi-to on dendritic extension following Aβ(25–35)-induced atrophy Figure 10
Effects of Kihi-to on dendritic extension following Aβ(25–35)-induced atrophy. Cortical neurons were cultured for 4 
days and then treated with or without (Cont) 10 μM Aβ(25–35). Four days after the administration of Aβ(25–35), the cells 
were treated with Kihi-to (0.01 and 0.1 μg/ml), 100 ng/ml of NGF, or vehicle (Veh). Five days after treatment, the cells were 
fixed and immunostained with an antibody against MAP2 (A). The lengths of MAP2-positive neurites (B) were quantified for 
each treatment. *p < 0.05 vs. Veh, n = 4 (one-way ANOVA followed by Holm-Sidak post hoc test). Scale bar = 100 μm.
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Effects of Kihi-to on Aβ(25–35)-induced cell death in cortical neurons Figure 11
Effects of Kihi-to on Aβ(25–35)-induced cell death in cortical neurons. After cultivation for 3 days, the cortical neu-
rons were treated with or without (Cont) Aβ(25–35). The cells were simultaneously treated with Kihi-to (1 μg/ml), [Gly14]-
Humanin (10 nM) or vehicle (Veh). Four days after the treatment, cell viability was measured (B). Photographs show represent-
ative images (A). Scale = 100 μm. *p < 0.05 vs. Cont, n = 4 (one-way ANOVA followed by Holm-Sidak post hoc test).
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Effects of Kihi-to on Aβ(25–35)-induced expression changes of calpain and calpastatin Figure 12
Effects of Kihi-to on Aβ(25–35)-induced expression changes of calpain and calpastatin. Cortical neurons were cul-
tured for 2 days and then treated with or without (C) 10 μM Aβ(25–35). The cells were simultaneously treated with Kihi-to 
(0.1 μg/ml, K), MDL28170 (1 nM, M), or vehicle (V) for 2, 8, 24 and 96 h, and then double-immunostained for calpain and 
MAP2 or for calpastatin and MAP2. Expression levels of calpain (A) and calpastatin (B) in MAP2-positive cells (neurons) were 
quantified. *p < 0.05 vs. Veh, n = 40. (one-way ANOVA followed by Holm-Sidak post hoc test).
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Effects of Kihi-to on Aβ(25–35)-induced Ca2+ influx Figure 13
Effects of Kihi-to on Aβ(25–35)-induced Ca2+ influx. Cortical neurons were cultured for 7 – 8 days and then loaded by 
fluo-4 AM (8 μM) for 40 min. After additional incubation for 30 min, cells were stimulated by 10 μM Aβ(25–35) alone (b; cir-
cles, n = 125) or 10 μM Aβ(25–35) and 1 μg/ml Kihi-to (b; squares, n = 83). Time-lapse images were captured every 5 s. Peak 
fluorescence change was calculated as relative change from baseline (ΔF/F%). Typical images were shown in (a). Scale bar = 10 
μm.
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to treatment slightly up-regulates the spatial memory also
in normal mice (data not shown). Semi-quantification
based on immunohistochemical comparisons suggested
that Kihi-to treatment resulted in increases in the densities
of axons especially in hippocampus CA1, the dentate
gyrus, parietal cortex, perirhinal cortex, and striatum.
Densities of presynapses were also increased in the hip-
pocampus and the cortex. In the perirhinal cortex, the
density of myelin was recovered. The hippocampus plays
a key role for memory storage, and has connections to cor-
tical and subcortical regions, the thalamus, hypothalamus
and basal ganglia in the brain [25]. Alzheimer's disease
model, Tg2576 mice show abnormalities in hippocampal
morphology and physiology and displayed spatial mem-
ory but not object recognition [26]. Although abundant
studies shows the hippocampus is crucial for memory
acquisition and recalling, it is still in controversy whether
the hippocampus is critical for familiarity recognition or
not [27]. By contrast, the perirhinal cortex mediates spa-
tial memory retention [28] and is also crucial for the dis-
crimination and memorization of novel and familiar
individual objects [29]. In addition, the parietal cortex is
essential for long-term spatial memory [30] and object
recognition [31] in rats. In combination with the present
data, these observations suggest that Kihi-to can attenuate
losses of axons, synapses and myelin in critical areas for
memory recall and recognition.
In vitro experiments demonstrated that Kihi-to restored
axonal and dendritic outgrowths (Figures 9 and 10) and
inhibited cell death (Figure 11) in Aβ(25–35)-treated cul-
tured cortical neurons. Although in immunohistochemis-
try of brain slices, increases in "densities" of P-NF-H-
positive and MAP2-positive stainings were indicated in a
Kihi-to-treated group, the increased densities may be
resulted from at least in part elongations of axons and
dendrites. Aβ(25–35) evoked neuritic abnormality and
cell death in our experiments at cellular level. These two
phenomena seem to be mediated by different cellular sig-
naling pathways. Heredia et al. reported that Aβ(1–40) or
Aβ(25–35) induced dramatic reduction in the axonal net-
work and the dystrophy related to actin remodeling in the
aberrant focal adhesion complex mediated by activations
of LIM kinase and cofilin [32]. Aβ(1–42)-induced axonal
degeneration was also inhibited by a calpain inhibitor in
an apoptosis-independent manner [33]. By contrast, cell
death triggered by Aβ seems to be mediated other cellular
mechanisms. Aβ(1–40) and Aβ(25–35) evoke cultured
cortical and hippocampal cell deaths associated with cas-
pase-3 activation [34]. Caspase inhibitors blocks Aβ(1–
42)-induced apoptosis [33]. Aβ(25–35)-induced cell
death is also known to be mediated by c-Jun N-terminal
kinase activation [35]. Therefore, Kihi-to may have inhib-
itory potentials against neuritic dystrophy and cell death
possibly by multi mechanisms. As shown in Figure 13,
Kihi-to antagonized Aβ(25–35) actions such as Ca2+ entry.
The Aβ-induced Ca2+ efflux elicits activations of caspase-9
and caspase-3, resulting in neuronal apoptosis [36].
Simultaneously treated Kihi-to with Aβ(25–35) inhibited
neuronal death (Figure 11) and Ca2+ entry (Figure 13).
These suggest that Kihi-to may repress neuronal death at
least in part by Aβ-induced Ca2+ entry. In our experiments
[37], Aβ injection into the brain elicits no apparent neu-
ronal death although treatment with Aβ induces cell death
in culture. However, the neuroprotective effect of Kihi-to
must be advantageous in the patient's brain where neuro-
nal death is severely progressing.
NF-H and MAP2 are substrates of the Ca2+-dependent
cysteine protease, calpain [20,21,30], the levels of calpain
are increased in the brains of patients with Alzheimer's
disease [22]. Calpain inhibition enhances neurite out-
growth in neuroblastoma SH-SY-5Y cells [38] and Aβ(1–
42)-treated sympathetic neurons [33], and increases
growth cone motility [39]. Therefore, we measured effects
of Kihi-to on the levels of calpain and calpastatin, an
intrinsic inhibitor of calpain. Interestingly, Kihi-to
showed sustained inhibition of the calpain level and
increase in the calpastatin level in neurons at least for 96
h (Figure 12). Aβ(25–25)-induced calpain increase and
calpastatin decrease occurred also in GFAP-positive astro-
cytes, and those were inhibited by Kihi-to-treatment (data
not shown). Further, the increase in calpain and decrease
in calpastatin were detected even at 26 days after injection
of Aβ(25–35) in mice brain, and those were attenuated by
Kihi-to treatment (Figure 8). The sustained activation of
the calpain system by Aβ(25–35) in very interesting. By
contrast an increase in calpain in Alzheimer's disease
brain [22], the calpastatin expression is markedly reduced
in the neocortex in Alzheimer's disease [40]. The expres-
sion of calpastatin could be regulated by calpain activity
since calpastatin is cleaved by calpain [41]. Further, previ-
ous studies have demonstrated an inverse correlation
between calpain and calpastatin expression levels in the
brain of Tg2576, a mouse model of Alzheimer's disease
[42]. Increased calpastatin inhibit Aβ(1–42)-induced
axonal degeneration in rat sympathetic neurons [33], sug-
gesting that inhibition of the calpain system may lead to
extension of neurites. The present results showed that
Kihi-to may inhibit the calpain system both in case of
simultaneous treatment with Aβ(25–35) in vitro (Figure
12) and post-treatment in vivo (Figure 8). Although it is
not known how Kihi-to regulates the expressions of cal-
pain and calpastatin, inhibitory potential of Kihi-to
against the calpain system may effect positively on neu-
ritic remodeling.
Conclusion
In conclusion Kihi-to clearly improved the memory
impairment and losses of neurites and synapses. Dysregu-BMC Complementary and Alternative Medicine 2008, 8:49 http://www.biomedcentral.com/1472-6882/8/49
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lation of expression levels of calpain and calpastatin by
Aβ(25–35) were also attenuated by Kihi-to. Natural med-
icines involving Japanese-Chinese traditional herbal
drugs, are not necessary in a position of just complemen-
tary medicines with only moderate effects. They are some-
times show clear-cut ameliorative effects. In our
preliminary data, all twelve crude drugs which composed
Kihi-to are needed to reveal the effect of neurite extension,
suggesting that we would lose sight of clear effects of Kihi-
to during isolation of active compounds. Therefore, we
are now inclusively investigating target molecules of Kihi-
to without isolation active constituents in it. After deter-
mination of several key target molecules, corresponding
compounds for each molecule could be analyzed. Kihi-to
is already available medicine to be prescribed by medical
doctors in Japan. Although further basic researches and a
lot of clinical studies should be needed, Kihi-to is a quite
attracting candidate for anti-dementia drug.
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